Frexalimab, an anti-CD40L monoclonal antibody, demonstrated significant and sustained improvements in disease activity and low relapse rates in patients with relapsing multiple sclerosis (MS) over approximately one year of treatment. These findings, presented at the American Academy of Neurology 2024 Annual Meeting, support the potential of frexalimab as a high-efficacy therapy for relapsing MS.